Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
HSD17B13 Inhibitor
HSD17B13-IN-54 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for investigating the role of HSD17B13 in various pathologies, including liver diseases, metabolic disorders, and cardiovascular conditions such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Additionally, it serves as a useful tool for studying drug-induced liver injury (DILI). -
HSD17B13 Inhibitor
HSD17B13-IN-96 is a potent inhibitor of 17 β-hydroxysteroid dehydrogenase (HSD17B13), exhibiting an IC50 value for estradiol of less than 0.1 μM. This compound is primarily utilized in research focused on nonalcoholic fatty liver disease (NAFLD) and related metabolic disorders. Its effectiveness in modulating HSD17B13 activity provides valuable insights into the biological pathways involved in liver metabolism and pathology. -
HSD17B13 Inhibitor
HSD17B13-IN-79 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for investigating liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). HSD17B13-IN-79 serves as an important tool for research aimed at understanding the role of HSD17B13 in these pathological conditions. -
HSD17B13 Inhibitor
HSD17B13-IN-91 is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value for estradiol ranging between 0.1 μM and 0.5 μM. This compound is utilized in research contexts focusing on liver diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as metabolic disorders and cardiovascular diseases. Additionally, it is relevant for studying drug-induced liver injury (DILI), making it a valuable tool for understanding the role of HSD17B13 in various pathological conditions. -
HSD17B13 Inhibitor
HSD17B13-IN-77 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of less than 0.1 μM for estradiol. This compound is valuable for research related to liver diseases and metabolic disorders, providing insight into the role of HSD17B13 in various physiological and pathological processes. Its application may enhance understanding of steroid metabolism and its implications in health and disease. -
HSD17B13 Inhibitor
HSD17B13-IN-20 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). This compound plays a crucial role in the modulation of estrogen metabolism and is particularly relevant in the study of liver diseases, including hepatitis, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma. HSD17B13-IN-20 provides valuable insights into the therapeutic targeting of HSD17B13 for the treatment and understanding of hepatic disorders. -
HSD17B13 Inhibitor
HSD17B13-IN-68 is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 value of less than 0.1 μM for estradiol. This compound is valuable for investigating the role of HSD17B13 in liver diseases and metabolic disorders, providing insights into potential therapeutic targets and mechanisms of action in these conditions. Its potency and specificity make it a useful tool for research in endocrinology and metabolic pathways. -
HSD17B13 Inhibitor
HSD17B13-IN-64 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for research focused on liver diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as metabolic disorders and drug-induced liver injury (DILI). Its selective inhibition of HSD17B13 may provide insights into therapeutic strategies for these conditions. -
17β-HSD10 Inhibitor
ESC1002755 is a selective inhibitor of 17β-HSD10, exhibiting an IC50 of 19 nM and demonstrating non-competitive inhibition against the cofactor NADH. This compound shows minimal cytotoxicity in HEK293 cells at a concentration of 50 μM, making it a promising tool for studies related to Alzheimer’s disease and hormone-dependent cancers, including prostate, bone, and colorectal cancer. Research applications include exploring the enzymatic mechanisms and therapeutic interventions associated with these conditions. -
HSD17B13 Inhibitor
HSD17B13-IN-11 is a selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting potent activity with an IC50 of ≤ 1 μM for leukotriene B3 and ≤ 0.1 μM for estradiol. This compound is valuable for investigating liver pathologies, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its role in metabolic and cardiovascular research also supports its utility in exploring potential therapeutic interventions. -
HSD17B13 Inhibitor
HSD17B13-IN-38 is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). This compound plays a significant role in the regulation of steroid metabolism and has potential implications in the study of liver and metabolic diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Researchers can utilize HSD17B13-IN-38 to explore its impact on cardiovascular diseases and related metabolic pathways. -
17β-HSD Inhibitor
HSD17B13-IN-23 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol and below 1 μM for leukotriene B3. This compound is significant in the study of nonalcoholic fatty liver diseases (NAFLDs), particularly in relation to nonalcoholic steatohepatitis (NASH). Its capacity to modulate HSD17B13 activity makes it a valuable tool for investigating the biochemical pathways involved in hepatic lipid metabolism and related disorders. -
HSD17B13 Inhibitor
HSD17B13-IN-88 is a potent inhibitor of 17β-Hydroxysteroid dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤0.1 μM for estradiol. This compound selectively modulates steroid hormone metabolism and has significant implications for research in metabolic disorders and liver diseases. Its ability to influence estradiol levels makes it a valuable tool for studying hormone-related pathways and therapeutic strategies. -
HSD17B13 Inhibitor
HSD17B13-IN-99 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of less than 0.1 μM for estradiol. This compound demonstrates significant potential for investigating liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Researchers can utilize HSD17B13-IN-99 to explore therapeutic strategies and mechanisms related to these health issues. -
HSD17B13 Inhibitor
HSD17B13-IN-22 is a selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). This compound demonstrates significant biological activity in modulating lipid metabolism and is relevant in the study of liver-related disorders, including hepatitis, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma. Its application in research enables a deeper understanding of HSD17B13's role in these conditions, potentially paving the way for therapeutic advancements. -
HSD17B13 Inhibitor
HSD17B13-IN-60 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. This compound is primarily utilized in research related to liver and metabolic diseases, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its inhibition of HSD17B13 makes it a valuable tool for understanding the underlying mechanisms of these disorders and developing potential therapeutic strategies. -
17β-HSD Inhibitor
HSD17B13-IN-18 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol and less than 1 μM for Leukotriene B3. This compound is significant in the context of nonalcoholic fatty liver diseases (NAFLDs), particularly in the study of nonalcoholic steatohepatitis (NASH). HSD17B13-IN-18 facilitates research aimed at understanding and potentially therapeutically targeting metabolic disorders related to liver function. -
17β-HSD1 Inhibitor
3-Acetyl-7-Hydroxycoumarin is a selective inhibitor of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1). It exhibits significant biological activity, demonstrating 57% inhibition of 17β-HSD1 at a concentration of 6 μM. This compound is valuable for research applications focused on hormone-dependent diseases, including breast cancer and endometriosis. -
HSD17B13 Inhibitor
HSD17B13-IN-94 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. This compound is instrumental in the investigation of liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its selective inhibition of HSD17B13 provides valuable insights into the underlying mechanisms of these diseases. -
AKR1C3 Inhibitor
S07-2005 (racemic) is a potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitor, exhibiting an IC50 value of 0.13 μM for AKR1C3 and 0.75 μM for AKR1C4. This compound demonstrates significant potential as a chemotherapeutic potentiator, particularly in overcoming resistance mechanisms in cancer treatment. Its selectivity and efficacy make it a valuable tool for research applications focused on cancer biology and drug resistance mechanisms. -
HSD17B13 Inhibitor
HSD17B13-IN-56-d3 is a selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for investigating the role of HSD17B13 in liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its inhibitory action makes it a significant tool for exploring therapeutic strategies targeting these conditions. -
17β-HSD Inhibitor
HSD17B13-IN-36 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol as a substrate. This compound is significant in the study of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH), making it valuable for research concerning metabolic disorders and liver health. Its selective inhibition of HSD17B13 may provide insights into therapeutic interventions for liver-related diseases. -
HSD17B13 Inhibitor
HSD17B13-IN-98 is a potent inhibitor of 17 β-hydroxysteroid dehydrogenase (HSD17B13), demonstrating an IC50 value for estradiol of less than 0.1 μM. This compound is particularly relevant in the investigation of nonalcoholic fatty liver disease, providing valuable insights into the biochemical pathways involved in lipid metabolism and liver function. Its specificity and efficacy make it an essential tool for research focused on metabolic disorders and related therapeutic strategies. -
HSD17B13 Inhibitor
HSD17B13-IN-59 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for research focused on liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its specific mechanism of action makes it an essential tool in elucidating the role of HSD17B13 in various pathophysiological contexts. -
17β-HSD1 Inhibitor
7-Coumaryl triflate is a selective inhibitor of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1), demonstrating an IC₅₀ of 360 nM and a Kᵢ of 173 nM. This compound selectively targets 17β-HSD2 while displaying no significant affinity for estrogen receptors ERα or ERβ. 7-Coumaryl triflate is valuable for research focused on hormone-dependent breast cancer and the modulation of estrogen metabolism. -
HSD17B13 Inhibitor
HSD17B13-IN-26 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). This compound exhibits significant activity in the modulation of steroid metabolism and demonstrates potential therapeutic applications in liver diseases, including hepatitis, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma. Researchers can utilize HSD17B13-IN-26 to further investigate the role of HSD17B13 in liver pathology and associated metabolic disorders. -
17β-HSD Inhibitor
4'-Hydroxyvalerophenone is a specific inhibitor of 17β-hydroxysteroid dehydrogenase (17β-HSD), exhibiting an IC50 value of 60.52 μM. This compound plays a significant role in steroid metabolism and can be utilized in various research applications related to hormonal regulation and steroid biosynthesis. Its inhibitory effects make it a valuable tool for studies investigating the role of 17β-HSD in physiological and pathological processes. -
17β-HSD5 Inhibitor
17β-HSD5 inhibitor 1 is a potent inhibitor of 17β-HSD5, demonstrating an IC50 of 2.9 nM in HEK-293 cells that overexpress human 17β-HSD5. This compound is primarily utilized in research applications related to steroid metabolism and is instrumental in studying the modulation of sex steroid biosynthesis. The selective inhibition of 17β-HSD5 can provide insights into its role in various hormonal disorders and therapeutic interventions. -
17β-HSD5 Inhibitor
17β-HSD5 inhibitor 2 is a potent inhibitor of 17β-hydroxysteroid dehydrogenase 5 (17β-HSD5), demonstrating an IC50 value of 40 nM. This compound is valuable for research into steroid metabolism and androgen biosynthesis, with potential applications in studying conditions related to hormone regulation and prostate cancer. Its inhibitory action enables the exploration of therapeutic strategies targeting 17β-HSD5 in various biological contexts. -
CHI3L1 Inhibitor
CHI3L1-IN-1 is a selective inhibitor of Chitinase-3-like protein 1 (CHI3L1), also known as YKL-40, with an IC50 of 50 nM. This compound exhibits additional effects by inhibiting the hERG channel with an IC50 of 2.3 μM. CHI3L1-IN-1 is valuable for research applications focused on the roles of CHI3L1 in inflammation and cancer, offering insights into its potential as a biomarker and therapeutic target. -
CYP2D6 Inhibitor
Guanfu base A is a potent noncompetitive inhibitor of CYP2D6, with a Ki value of 1.20 μM in human liver microsomes and 0.37 μM for the recombinant form. This antiarrhythmic alkaloid, derived from Aconitum coreanum, also exhibits competitive inhibition of CYP2D in monkey and dog microsomes, with Ki values of 0.38 μM and 2.4 μM, respectively. In addition to its CYP2D6 inhibitory activity, Guanfu base A demonstrates the ability to inhibit HERG channel current, making it relevant for studies in drug metabolism and cardiac electrophysiology. -
CYP2D6 Inhibitor
Guanfu base A hydrochloride is a selective inhibitor of the CYP2D6 enzyme, demonstrating significant potential in the management of arrhythmia-related disorders. This alkaloid exhibits inhibitory effects across various species, including humans, primates, and canines. Its ability to modulate CYP2D6 activity may provide valuable insights and therapeutic applications in pharmacology and toxicology research. -
5-LOX Inhibitor
5-O-Demethylnobiletin is an effective inhibitor of 5-lipoxygenase (5-LOX), exhibiting a potent IC50 of 0.1 μM without impacting COX-2 expression. This polymethoxyflavone, derived from Citrus jambhiri Lush., demonstrates notable anti-inflammatory properties by inhibiting leukotriene B4 (LTB4) production in rat neutrophils and elastase release in human neutrophils with an IC50 value of 0.35 μM. 5-O-Demethylnobiletin is valuable for research applications related to inflammation and leukotriene signaling pathways. -
5-LO Inhibitor
Enofelast (BI-L-239) is a selective inhibitor of 5-lipoxygenase (5-LO) with an IC50 of 2.48 μM, effectively blocking calcium ionophore-induced leukotriene B4 (LTB4) production. Its ability to modulate lipid mediators makes it a valuable tool for studying inflammatory pathways and leukotriene signaling in various biological contexts. Enofelast is suitable for research applications investigating the role of 5-LO in diseases associated with inflammation and immune response. -
PA2/5-LOX/COX Inhibitor
LY256548 is a potent inhibitor of phospholipase A2, 5-lipoxygenase (5-LOX), and cyclooxygenase (COX), demonstrating significant anti-ischemic and anti-inflammatory properties. This compound effectively reduces leukotriene B4 production in response to A23187 stimulation. In preclinical models, LY256548 has shown efficacy in mitigating bone damage and paw swelling in rat models of Freund's complete adjuvant-induced arthritis (FCA), making it a valuable tool for research into inflammatory diseases and analgesic mechanisms. -
Cyclooxygenase/Lipoxygenase Inhibitor
L-652343 is a dual inhibitor of cyclooxygenase and lipoxygenase enzymes. It effectively inhibits the production of leukotriene B4 (LTB4) in isolated human polymorphonuclear leukocytes, demonstrating an IC50 value of 1.4 μM when challenged with Calcimycin. This compound is applicable in the study of inflammatory and immune diseases, providing insights into the mechanisms of these conditions and potential therapeutic interventions. -
5-LO Inhibitor
5-LOX-IN-6 is a potent and selective inhibitor of 5-lipoxygenase (5-LO), exhibiting reversible inhibition. It effectively reduces 5-LO activity in human neutrophils and recombinant human 5-LO with IC50 values of 0.23 µM and 0.086 µM, respectively. By inhibiting leukotriene biosynthesis, 5-LOX-IN-6 serves as a valuable tool in the study of inflammatory and allergic disorders. -
5-LOX Inhibitor
E 6080 is a specific inhibitor of 5-lipoxygenase (5-LOX), exhibiting an IC50 of 0.2 μM in rat basophilic leukemia cells. This compound effectively reduces leukotriene release, which is critical in the inflammatory response. E 6080 has demonstrated the ability to inhibit bronchospasm induced by antigen inhalation in sensitized guinea pigs, making it a valuable tool for asthma research and related inflammatory conditions. -
5-LOX Inhibitor
A63162 is a selective inhibitor of 5-lipoxygenase (5-LOX), a key enzyme in the biosynthesis of leukotrienes. This compound effectively inhibits both mitogen-induced proliferation of horse mononuclear cells and the synthesis of leukotriene LTB4 in response to Calcimycin at equivalent concentrations. A63162 is useful in research focused on chronic obstructive pulmonary disease, arthritis, and inflammatory bowel disease, offering insights into inflammatory pathways and potential therapeutic interventions. -
CETP Inhibitor
Obicetrapib is a potent cholesteryl ester transfer protein (CETP) inhibitor that effectively reduces atherogenic lipoproteins, including LDL-C, ApoB, and lipoprotein(a), while simultaneously increasing HDL-C levels. This compound is of significant interest in research related to dyslipidemia and atherosclerotic cardiovascular disease (ASCVD), facilitating investigations into lipid metabolism and cardiovascular health outcomes. -
Acetylcholinesterase Inhibitor, Butyrylcholinesterase Inhibitor, Carbonic Anhydrase I/II Inhibitor, α-Glycosidase Inhibitor
Vescalagin is a hexahydroxyphenol that acts as an inhibitor of acetylcholinesterase and butyrylcholinesterase, as well as carbonic anhydrases I and II, and α-glycosidase. It demonstrates potent inhibitory activity with Ki values of 5.87 nM for AChE, 3.89 nM for BChE, 11.75 nM for hCA I, 16.23 nM for hCA II, and 16.08 nM for α-glycosidase. Vescalagin exhibits non-competitive inhibition for hCA I, hCA II, and α-glycosidase, while also reducing hyperglycemia and hypertriglyceridemia in dietary models. Additionally, it possesses anti-inflammatory and antioxidant activities, making it a valuable compound for research in diabetes and metabolic disorders. -
IDO1 Inhibitor
IDO1-IN-19 is a selective inhibitor of Indoleamine 2,3-dioxygenase 1 (IDO1), exhibiting an IC50 value of 8.64 μM for CYP2C9. In addition, it modulates cardiac ion channels with IC50 values of 12 μM for IKr, 40 μM for INa, and 8.3 μM for ICa. This compound is valuable for investigating the mechanisms of cancer biology and has potential applications in cancer therapeutics. -
NMT Inhibitor
Myristoyl Coenzyme A Lithium is a specific inhibitor of N-myristoyltransferase (NMT), which plays a critical role in myristoylation, a process that is vital for viral proliferation and has increased activity in colon epithelial tumors compared to normal cells. This compound functions by blocking the demyristoylation process, thereby regulating NMT activity, which may contribute to its potential anticancer and antiviral properties. Myristoyl Coenzyme A Lithium is valuable for research applications focusing on cancer biology and viral infection mechanisms. -
Lipoxygenase Inhibitor
4-Nitrocatechol is a potent inhibitor of lipoxygenase, an enzyme implicated in the metabolism of arachidonic acid and the biosynthesis of inflammatory mediators. This compound exhibits significant anti-inflammatory properties and is widely used in research to explore the roles of lipoxygenase in various biological processes. Its application extends to studies of oxidative stress and the development of novel therapeutic strategies targeting inflammatory diseases. -
Endogenous Metabolite,Cancer Inhibitor
Protoporphyrin IX (disodium) is a key metabolite in the heme biosynthetic pathway, functioning primarily as a radiation sensitizer. It enhances the generation of reactive oxygen species (ROS) even under hypoxic conditions, thereby inducing DNA damage. This compound also serves as a photosensitizer, undergoing photodegradation when exposed to light. Notably, Protoporphyrin IX (disodium) accumulates in tumor cells following administration of 5-aminolevulinic acid (5-ALA) and demonstrates selective efficacy against basal cell carcinoma when activated at a wavelength of 405 nm. Its properties make it a valuable candidate for research into sonodynamic and photodynamic therapies for various cancers, including bladder cancer. -
PPO Inhibitor
PPO-IN-10 is a selective inhibitor of protoporphyrinogen IX oxidase (PPO), functioning through its 2-phenylpyridine pyrrolidone scaffold. By inhibiting PPO, this compound induces the accumulation of photosensitive protoporphyrin IX, ultimately leading to necrosis in target weed leaves. PPO-IN-10 serves as a valuable tool in research aimed at the development of novel PPO herbicides. -
Protoporphyrinogen IX Inhibitor
PPO-IN-2 is a potent inhibitor of protoporphyrinogen IX oxidase, exhibiting a Ki value of 16 nM. This compound effectively disrupts heme biosynthesis by targeting the conversion of protoporphyrinogen IX to protoporphyrin IX. PPO-IN-2 is valuable for research into porphyrias and other disorders related to heme metabolism, providing insights into potential therapeutic strategies. -
PPO Inhibitor
PPO-IN-3 is a potent protoporphyrinogen oxidase (PPO) inhibitor, exhibiting a KI value of 0.67 nM. This compound demonstrates effective post-emergence herbicidal activity, making it valuable for agricultural applications aimed at weed control. Its specific mechanism of action provides a useful tool for research into herbicide efficacy and resistance mechanisms. -
Protoporphyrinogen Oxidase Inhibitor
Herbicidal agent 2 is a protoporphyrinogen oxidase (PPO) inhibitor that demonstrates effective herbicidal activity against a range of broadleaf and monocotyledon weeds. This compound serves as a valuable tool in agricultural research for studying herbicide resistance and developing new weed management strategies. Its targeted mechanism offers insights into the inhibition of crucial enzymatic pathways involved in plant growth and development. -
PPO Inhibitor
PPO-IN-7 is a potent inhibitor of protoporphyrinogen oxidase (PPO), a key enzyme involved in heme biosynthesis. This compound demonstrates significant herbicidal activity, making it valuable for research applications in plant biology and agricultural chemistry. Its ability to inhibit PPO provides insights into metabolic pathways and offers potential development avenues for herbicide formulations.
